Soleno Therapeutics (SLNO) Shares Outstanding (Diluted Average) (2014 - 2026)

Soleno Therapeutics (SLNO) has 9 years of Shares Outstanding (Diluted Average) data on file, last reported at $53.1 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 14.92% year-over-year to $53.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.1 million (up 14.92% YoY) and the FY2025 annual result came in at $52.4 million, up 30.39% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $53.1 million in Q1 2026 per SLNO's latest filing, from $52.4 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $53.1 million in Q1 2026 and bottomed at $5.3 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $26.4 million (2023), against an average of $27.1 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) slumped 90.79%; it then jumped 288.72% in 2024.
• Tracing SLNO's Shares Outstanding (Diluted Average) over 5 years: stood at $8.4 million in 2022, then jumped by 96.4% to $16.5 million in 2023, then soared by 143.61% to $40.2 million in 2024, then jumped by 30.39% to $52.4 million in 2025, then increased by 1.3% to $53.1 million in 2026.
• Per Business Quant, the three latest SLNO Shares Outstanding (Diluted Average) figures stand at $53.1 million (Q1 2026), $52.4 million (Q4 2025), and $50.5 million (Q2 2025).

Peer Comparison